Blue Matter Blog

Oncology Trends Part III: Critical Capabilities For a Successful Future
September 5, 2019

Future Trends In Parts I and II of this series, we reviewed the dramatic diagnostic and pharmaceutical advances over the past 5 years that have rapidly enhanced the standard of care, leading to significant and essentially curative outcomes for some patients. In this article, we discuss the near-term future – the possibilities as well as …

They Did It! Blue Matter Team Completes the South Coast Challenge.
September 4, 2019

This past weekend (31 August – 1 September), a team from Blue Matter took part in the South Coast Challenge to help raise money for cancer research.  Zeren Kocak, Linah Richer, Anwen Brown, Nafees Masri, Mariah Peixoto, and Magda Palczynska put on their hiking shoes and hit the trail to raise funds for Cancer Research …

Seven Keys to Success in Europe
August 26, 2019

For US-based biopharmaceutical companies seeking to expand, establishing a presence in Europe is usually an obvious next step.  Investors typically expect that a company will avail itself of such a large market opportunity and unlock the full commercial value of its assets. Europe represents the second largest market in the world for prescription pharmaceuticals.  The …

Blue Matter Ranked as One of the 50 Best Consulting Firms to Work for in North America
August 20, 2019

We are very excited to report that Blue Matter has joined the Vault Consulting 50 for 2020, earning a ranking as one of the 50 best consulting firms to work for in North America.  This was our first year participating in Vault’s annual survey.  Among all consulting firms surveyed, Blue Matter ranked #30.  Among boutique …

Blue Matter Team Gets Ready to Walk the South Coast to Raise Money for Cancer Research
July 25, 2019

The weekend of 31 August – 1 September will be a busy one for Blue Matter team members Zeren Kocak, Linah Richer, Anwen Brown, Nafees Masri, Mariah Peixoto, and Magda Palczynska.  They’ll be putting on their hiking shoes and taking part in this year’s South Coast Challenge to help raise money for cancer research. The …

Oncology Trends: Is Past Performance Predictive of Future Returns? – Part II, Unmet Needs & Future Advancements
July 16, 2019

In Part I of this series, we identified and described four key trends in oncology: Novel Drug Targets and Classes of Therapy Novel Drug Designs Tumor Biology-Based Regimens Diagnostic-Driven, Adaptive Regimens: Precision Medicine Despite the significant advances these trends represent, much unmet need remains in oncology. In this installment, we outline some of those key …

Oncology Trends: Is Past Performance Predictive of Future Returns? – Part I, Trends Overview
July 8, 2019

Over the past 5 years, several ground-breaking advancements in oncology have dramatically advanced the standard of care. These new classes of drugs include the PD(L)1 checkpoint inhibitors, the PARP inhibitors, and the EGFR resistance targeted drugs.  Also included is a general trend towards more precise and targeted treatment decisions, driven by incorporating molecular tests and …

Blue Matter Breakfast Club 2, Nick Leschly, CEO of bluebird bio
Blue Matter Breakfast Club Meeting #2 – A Discussion with Nick Leschly, CEO of bluebird bio
July 1, 2019

The Blue Matter Breakfast Club is an ongoing series of quarterly two-hour breakfast forums, hosted by our Rare Diseases Team.  These forums bring together leaders from companies that develop and commercialize rare disease therapies to discuss critical business issues. The second Breakfast Club meeting was on 17th June 2019 at Skylounge restaurant in Zug, Switzerland.  The …

Precision Medicine Part III: Co-Evolution of Diagnostics and Pharma Development
April 23, 2019

Better integration of personalized cancer treatments into clinical practice will immensely improve outcomes for patients. But, to achieve the full potential of precision medicine, both pharma and diagnostics must accelerate and broaden their scope of precision medicine beyond their currently limited settings and ensure successful integration into clinical practice. In this installment, we will explore …

Precision Medicine Part II: Current Utility and Challenges in the Clinic
April 8, 2019

Over the past few decades in oncology, targeted therapies—and the tests that identify which tumors will be sensitive to them—have significantly advanced the standard of care in several key settings. However, precision medicine will not achieve its full potential in oncology without broader success in pharmaceutical and diagnostic development, and better integration of both into …

Introducing the Blue Matter Breakfast Club Series
March 27, 2019

Recently, our Rare Diseases Team launched the Blue Matter Breakfast Club.  You might ask, “What is the Blue Matter Breakfast Club?”  Well, it’s an ongoing series of quarterly two-hour breakfast forums, hosted by our Rare Diseases Team.  These forums bring together leaders from companies that develop and commercialize rare disease therapies to discuss critical business …

Precision Medicine Part I: The Science Behind Molecular Testing
March 18, 2019

Since scientists first sequenced the human genome nearly 20 years ago, we have all been increasingly enthusiastic about the potential for precision medicine to better diagnose and treat diseases. In oncology, targeted therapies against specific mutations have already demonstrated this promise, though only in the relatively limited settings where these therapies exist and testing is …

Building a Winning Differentiation Strategy in Oncology: Maximizing the End-to-End Stakeholder Experience
March 7, 2019

Part Four in a Series on Oncology Product Commercialization As we’ve written before, oncology launches are occurring more frequently, largely due to a rapidly evolving understanding of disease biology and massive investments in oncology research and development.  As a result, many indications are becoming more complex and competitive, with a greater number of approved molecules …

Are You Happy at Work? – A Peek at Blue Matter’s Global Happiness Survey
February 18, 2019

On February 1, Blue Matter launched its first Global Happiness Survey.  This monthly survey asks Blue Matter team members around the world to rate their current levels of happiness.  Even though the global survey just got started, the idea of measuring team happiness has a lengthy history within the firm, starting as regional efforts in …

Helping in the Fight Against Lung Cancer: The Addario Lung Cancer Foundation
February 11, 2019

At Blue Matter, we love what we do.  The work is interesting, and we always feel like we’re learning something new. There’s also a sense that, in our own small way, we’re joining in the fight against some of the world’s worst diseases.  Our team members have a passion for the areas in which they …

A Framework for Successfully Launching & Commercializing Rare Disease Products
January 28, 2019

Regardless of the product, launching a new biopharmaceutical drug is a time-consuming, expensive, and complex undertaking.  It requires sound strategy, expert planning, and effective cross-functional coordination to get everything done right.  The analogy is certainly not new but launch really is akin to conducting a symphony orchestra, ensuring that all members play their parts correctly, …

Cell-Based Cancer Immunotherapies: Commercial Risk, Curative Reward, Part Two
January 21, 2019

Part Two of a Two-Part Series:  Commercial Opportunity, Challenges, and Outlook In Part One of this series, we provided an overview of how the immune system can fight cancer, as well as the reasons it can sometimes fail in the effort.  In addition, we explored an extremely interesting class of therapies that show great promise …

Cell-Based Cancer Immunotherapies: Commercial Risk, Curative Reward, Part One
January 18, 2019

Part One of a Two-Part Series:  How Cancer Immunity Works & Types of Cell-Based Immunotherapy Until recently, cancer treatments for advanced disease were palliative in nature, seeking to reduce tumor burden and prolong life.  Curing metastatic disease was not considered possible. But over the past few decades, a new class of cancer treatments has demonstrated curative …

The Complex Oncology Audience
December 13, 2018

Part Three in a Six-Part Series on Oncology Product Commercialization In Part One of this series, we outlined five commercial challenges in oncology that biopharma decision-makers must face.  Part Two dealt with the first of those challenges, the “constant state of launch” that now exists in oncology.  In this installment, we introduce the complex array …

The Disruptive Potential of Gene Therapy: When will it fully realize its commercial potential?
December 7, 2018

Gene therapy has made significant advances over the past few years.  However, those therapeutic advances have not been accompanied by spectacular commercial successes, at least not yet.  This raises a simple question: When will gene therapy fully realize its commercial potential? We explored that question with a distinguished panel on November 7, 2018 at the …